Marianne Bjordal
Partner @ 3B Future Health Fund
Nice, France
Marianne Bjordal is a seed investor at 3B Future Health Fund in Nice focused on Biotechnology and Medical. Marianne Bjørdal joined 3B Future Health Fund in 2018 where she is a partner. She has more than 15 years experience in research and early stage investment. Prior to joining 3B Future Health, Marianne worked as a researcher for the French National Centre for Scientific Research (CNRS). She is a former Marie Curie Early-Stage Researcher and wasawarded the AXA Prize from the French Academy of Science in 2014. Marianne received an M.Sc. in Molecular Biology from the University of Bergen in Norway, a Ph.D. in Molecular and Cellular Biology from the University of Nice in France and an MBA from the IAE Nice Graduate School of Management, France.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Marianne Bjordal invests in
Stages Marianne Bjordal invests in
Countries Marianne Bjordal invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 1 (25%)
- Genetics 1 (25%)
- Biopharma 1 (25%)
- Health Care 1 (25%)
Stage
- Seed 1 (25%)
- Series A 1 (25%)
- Series B 1 (25%)
Country
- Italy 1 (25%)
- United Kingdom 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Epsilogen
|
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $16.3M / Series B / Sep 09, 2024 | |
Sibylla Biotech
|
Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas. | $23M / Series A / Oct 04, 2022 | |
|
Epsilogen
|
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $41.2M / Series B / Mar 02, 2022 | |
GenEp
|
GenEp, Inc. is a pre-clinical stage biotechnology company based on intellectual property assets. GenEp creates therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment-resistant epilepsies. | $1.5M / Seed / Oct 26, 2021 |
Co-Investors
Novartis Venture Fund
3 deals together
ALSA Ventures
2 deals together
British Patient Capital
2 deals together
Epidarex Capital
2 deals together
About 3B Future Health Fund
Helsinn Investment Fund S.A. is a Luxembourg fund focused on early-stage investments in areas of high unmet patient need.
3B Future Health Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Carlos von Bonhorst
Strategic Consultant
|
|||
|
Marianne Bjordal
Partner
|
|||
Riccardo Braglia
Vice Chairman and Chief Executive Officer
|
|||
Francesco Granata
Consultant
|
|||
Karin Hehenberger
Medical and Scientific Consultant
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Marianne Bjordal invest in?
Marianne Bjordal invests primarily in Biotechnology, Medical and Genetics startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Marianne Bjordal last invest?
The most recent investment recorded for Marianne Bjordal closed in Sep 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
